Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding

Analysis Builds on Consistently Demonstrated Positive Outcomes for VASCEPA/VAZKEPA Across Sub-Populations in REDUCE-IT, Including in Patients with Prior Myocardial Infarction (MI), Prior Revascularization, Prior Peripheral Arterial Disease (PAD) and Diabetes

Amarin Corporation announced today new data from a post-hoc analysis of the acclaimed REDUCE-IT study, revealing that Icosapent Ethyl (IPE) significantly reduced the risk of first and total ischemic events by 37% and 36% respectively in patients with recent Acute Coronary Syndrome (ACS), all without an increased risk of bleeding.

This latest analysis only adds to the substantial evidence showing the positive impact of VASCEPA/VAZKEPA across various sub-populations in the REDUCE-IT study. Previous data has highlighted the benefits of these medications in patients with a history of Myocardial Infarction (MI), revascularization procedures, Peripheral Arterial Disease (PAD), and diabetes.

Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showcasing Continued Cardiovascular Benefits

This exciting new data was presented at the 2023 American College of Cardiology (ACC) Scientific Session (ACC.23) in conjunction with the World Congress of Cardiology (WCC). The findings are expected to have a significant impact on the treatment of patients with cardiovascular disease, especially those who have recently experienced an ACS event.

How This Will Affect Me

For individuals with recent ACS or other cardiovascular risk factors, this new data suggests that treatment with VASCEPA/VAZKEPA could significantly reduce the risk of future ischemic events without increasing the risk of bleeding. This may offer a new and effective treatment option for improving cardiovascular outcomes and reducing the overall burden of heart disease.

How This Will Affect the World

The implications of these findings extend beyond individual patients to the broader healthcare landscape. By demonstrating the consistent cardiovascular benefits of IPE in various patient populations, this data has the potential to inform updated treatment guidelines and improve the standard of care for cardiovascular disease on a global scale. Ultimately, this could lead to better outcomes for countless individuals at risk for heart-related events.

Conclusion

The new post-hoc analysis from Amarin Corporation’s REDUCE-IT study represents a significant advancement in the field of cardiovascular medicine. By showcasing the consistent positive outcomes of IPE treatment in patients with recent ACS and other high-risk conditions, this data has the potential to revolutionize the way we approach cardiovascular care. As we look towards a future where heart disease remains a leading cause of death worldwide, these findings offer hope for better outcomes, improved quality of life, and ultimately, a healthier world for us all.